Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AQST Stock Forecast 2026-2027
$4.17
Current Price
$523.13M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AQST Price Targets
+163.8%
To High Target of $11.00
+115.8%
To Median Target of $9.00
+43.9%
To Low Target of $6.00
AQST Price Momentum
+6.6%
1 Week Change
0.0%
1 Month Change
+21.9%
1 Year Change
-35.4%
Year-to-Date Change
-44.8%
From 52W High of $7.55
+42.3%
From 52W Low of $2.93
📊 TOP ANALYST CALLS
Did AQST Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aquestive is one of their latest high-conviction picks.
Latest AQST Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, AQST has a bullish consensus with a median price target of $9.00 (ranging from $6.00 to $11.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $4.17, the median forecast implies a 115.8% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AQST Analyst Ratings
9
Buy
0
Hold
0
Sell
AQST Price Target Range
Low
$6.00
Average
$9.00
High
$11.00
Current: $4.17
Latest AQST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AQST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $8.00 |
| Oct 9, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Sep 8, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jun 17, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 2, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Assumes | $7.00 |
| May 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 2, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 10, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 7, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Dec 20, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 25, 2024 | Leerink Partners | Outperform | Maintains | $N/A | |
| Oct 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 8, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Sep 30, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Sep 30, 2024 | Leerink Partners | Outperform | Reiterates | $N/A | |
| Sep 30, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Aquestive Therapeutics Inc (AQST) Competitors
The following stocks are similar to Aquestive based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AQST
Aquestive Therapeutics
mkt cap
523.13M
Aquestive Therapeutics Inc (AQST) Financial Data
Aquestive Therapeutics Inc has a market capitalization of $523.13M with a P/E ratio of -5.3x. The company generates $50.27M in trailing twelve-month revenue with a -137.1% profit margin.
Revenue growth is +65.7% quarter-over-quarter, while maintaining an operating margin of -29.1% and return on equity of +248.9%.
Valuation Metrics
Market Cap
$523.13M
Enterprise Value
$455.97M
P/E Ratio
-5.3x
PEG Ratio
0.1x
Price/Sales
10.4x
Growth & Margins
Revenue Growth (YoY)
+65.7%
Gross Margin
+76.0%
Operating Margin
-29.1%
Net Margin
-137.1%
EPS Growth
+65.7%
Financial Health
Cash/Price Ratio
+21.2%
Current Ratio
4.1x
Debt/Equity
-1.3x
ROE
+248.9%
ROA
-28.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aquestive Therapeutics Inc (AQST) Business Model
About Aquestive Therapeutics Inc
What They Do
Develops innovative drug delivery technologies.
Business Model
The company generates revenue by manufacturing and supplying proprietary drug delivery products, which are licensed to partners for commercialization. It primarily focuses on orally administered medicines, providing non-invasive alternatives to traditional therapies, while also collaborating with pharmaceutical partners to develop new molecules using its PharmFilm® platform.
Additional Information
Aquestive Therapeutics has a portfolio of commercialized products, including Suboxone® and Sympazan®, and is advancing its pipeline with late-stage products for severe allergic reactions and epilepsy. The company is committed to enhancing patient accessibility through its quick-dissolving formats, which are particularly beneficial in urgent medical situations.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
147
CEO
Mr. Daniel Barber
Country
United States
IPO Year
2018
Website
www.aquestive.comAquestive Therapeutics Inc (AQST) Latest News & Analysis
Latest News
Quick Summary
Aquestive Therapeutics (AQST) plans to resubmit its new drug application for Anaphylm in Q3 2026, reporting higher Q1 revenue and a narrower net loss.
Why It Matters
Aquestive’s progress on the Anaphylm application and improved financials indicate potential growth, which may enhance investor confidence and influence stock performance.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Aquestive Therapeutics, Inc. (AQST) held its Q1 2026 earnings call, providing updates on financial performance and business developments. Further details can be found in the transcript.
Why It Matters
AQST's Q1 2026 earnings call reveals key financial performance and strategic direction, impacting stock valuation and investor sentiment regarding future growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
1 month ago
Quick Summary
Aquestive Therapeutics, Inc. reported its Q1 2026 financial results and provided a strategic business update, focusing on advancing innovative medicines and delivery technologies.
Why It Matters
Aquestive Therapeutics' Q1 financial results and strategic update may signal growth potential or risks, influencing stock performance and investor sentiment in the pharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aquestive Therapeutics (AQST) reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of $0.14 and an improvement from a loss of $0.24 per share a year earlier.
Why It Matters
Aquestive Therapeutics' smaller than expected loss signals improved financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Aquestive Therapeutics (AQST) reported its financial results for Q1 2026. Investors should compare key metrics to Wall Street estimates and year-ago values for insights.
Why It Matters
Key metrics relative to Wall Street estimates and prior year performance can indicate growth potential and market expectations for Aquestive Therapeutics, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Aquestive Therapeutics, Inc. has refinanced its existing debt with a new $150 million facility from Oaktree Capital Management, aimed at enhancing its pharmaceutical development efforts.
Why It Matters
Aquestive Therapeutics' $150 million debt refinancing with Oaktree Capital may enhance liquidity, improve financial stability, and enable further investments in innovation, impacting future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AQST Stock
What is Aquestive Therapeutics Inc's (AQST) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Aquestive Therapeutics Inc (AQST) has a median price target of $9.00. The highest price target is $11.00 and the lowest is $6.00.
Is AQST stock a good investment in 2026?
According to current analyst ratings, AQST has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AQST stock?
Wall Street analysts predict AQST stock could reach $9.00 in the next 12 months. This represents a 115.8% increase from the current price of $4.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aquestive Therapeutics Inc's business model?
The company generates revenue by manufacturing and supplying proprietary drug delivery products, which are licensed to partners for commercialization. It primarily focuses on orally administered medicines, providing non-invasive alternatives to traditional therapies, while also collaborating with pharmaceutical partners to develop new molecules using its PharmFilm® platform.
What is the highest forecasted price for AQST Aquestive Therapeutics Inc?
The highest price target for AQST is $11.00 from at , which represents a 163.8% increase from the current price of $4.17.
What is the lowest forecasted price for AQST Aquestive Therapeutics Inc?
The lowest price target for AQST is $6.00 from at , which represents a 43.9% increase from the current price of $4.17.
What is the overall AQST consensus from analysts for Aquestive Therapeutics Inc?
The overall analyst consensus for AQST is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are AQST stock price projections?
Stock price projections, including those for Aquestive Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 5:38 AM UTC